

RECEIVED  
CENTRAL FAX CENTER

JUL 13 2006

Application No.: 10/019,049  
Inventor: Rosenberg et al.  
Reply to Office Action of 13 March 2006  
Docket No.: 0480/01221

**Amendments to the Claims:**

- 1.-3. (canceled)
4. (previously presented) A process for producing a solid or semisolid preparation which is substantially free of volatile organic solvent, said preparation comprising paroxetine or one of its physiologically acceptable salts in the form of a molecular dispersion in a pharmaceutically acceptable matrix material which comprises a completely synthetic polymer having a glass transition temperature of  $>90^{\circ}\text{C}$  in the anhydrous state, which process comprises the paroxetine or one of its salts and the matrix material being mixed to give a homogeneous melt in an extruder and subsequently being shaped.
5. (previously presented) The process of claim 4, wherein the preparation comprises paroxetine hydrochloride in the form of molecular dispersion in the matrix material, and wherein paroxetine is processed with ammonium chloride and the matrix materials to give a homogeneous melt.
6. (previously presented) The process of claim 5, wherein amorphous paroxetine or one of its physiologically acceptable salts is employed.
7. (previously presented) The process of claim 4, wherein the melt is produced at a temperature in the range of 80 to  $150^{\circ}\text{C}$ .
8. (previously presented) The process of claim 4, further comprising applying a vacuum to the extruder while the paroxetine or one of its salts and the matrix material are being mixed if solvents are present therein.
- 9.-19. (canceled)